Bicycle Therapeutics posts investor presentation highlighting Bicycle molecule platform and oncology pipeline

The presentation highlighted tolerability at clinically active doses; 161 patients exposed in BT5528-100, with no hemorrhage events reported to date.

The company reported cash and cash equivalents of $510.1 million as of June 30, 2026, with expected runway into 2030.

Bicycle Therapeutics outlined an oncology-focused pipeline built on its Bicycle molecules platform, spanning drug conjugates, radioligands, and imaging agents.

Lead asset nuzefatide pevedotin targets EphA2, positioned as first-in-class; Phase 2 open-label trial underway in second-line or later pancreatic cancer.